Request for Proposals: Efficacy of Lebrikizumab in patients with fibrosing skin conditions
Supports independent clinical research on the efficacy of lebrikizumab in treating fibrosing skin conditions, aiming to advance dermatological science.
Funder: Eli Lilly and Company
Due Dates (Anticipated): February 2027
Funding Amounts: Funding and/or provision of study drug; award size and duration are determined based on the scope of the proposed research.
Summary: Supports investigator-initiated clinical research on the efficacy of lebrikizumab in patients with fibrosing skin conditions.
Description
This grant opportunity, provided by Eli Lilly and Company, seeks investigator-initiated research proposals focused on studying the efficacy of lebrikizumab in patients with fibrosing skin conditions. Approved projects will be designed, conducted, and sponsored by the grantees, with oversight and review by Lilly scientific committees and potentially external experts. The aim is to advance clinical understanding in dermatology through independent research aligned with Lilly’s research interests.
